Trial Profile

A Phase 1b, Open-label Study of the Safety and Pharmacokinetics of EDG-5506 in Adults With Becker Muscular Dystrophy

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Oct 2024 According to an Edgewise Therapeutics media release, the study will be presented at the 29th International Annual Congress of the World Muscle Society (WMS). The conference will take place at The Prague Congress Centre in Prague, Czechia, October 8-12, 2024.
18 Apr 2024 Results (n=12) assessing Effects of EDG-5506, a Fast Myosin Modulator, on Function and Biomarkers of Muscle Damage in Adults with Becker Muscular Dystrophy presented at the 76th Annual Meeting of the American Academy of Neurology 2024
15 Apr 2024 According to Edgewise Therapeutics Media Release, data from this study will be presented at the American Academy of Neurology 2024 Annual Meeting Podium Presentation.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com